Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | TTR | P02766 | 3/20 | 0.77 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.65 |
| ▸ | TUBB | P07437 | 2/20 | 0.65 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.65 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.65 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.65 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.65 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.65 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.65 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.65 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.65 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574065 | 1.00 | LMNA (0.77) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL1808387 | 0.93 | MEN1 (0.84) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL1808386 | 0.93 | MEN1 (0.84) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL18471992 | 0.90 | LMNA (0.69) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL3688258 | 0.89 | KDM4E (0.67) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL3688259 | 0.89 | KDM4E (0.67) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL10941162 | 0.89 | MAPT (0.81) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL2451780 | 0.89 | MAPT (0.81) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL11354408 | 0.89 | MAPT (0.81) | LMNAMAPTKDM4EMEN1KMT2A | |
| SCHEMBL16130494 | 0.88 | KDM4E (0.69) | LMNAMAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | claimed |
| CN-119454487-A | Preparation method and application of resveratrol and derivative thereof | 上海相宜本草化妆品股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12029706-B2 | Methods for treating mucopolysaccharidosis | UNIVERSITY OF MIAMI (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029706-B2 | Methods for treating mucopolysaccharidosis | UNIVERSITY OF MIAMI (US) | 2024-07-09 | — | — | US | disclosed |
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11419841-B2 | Uses of lipophenolic compounds | UNIVERSITE DE MONTPELLIER | 2022-08-23 | — | — | US | disclosed |
| EP-3134421-B1 | NEW LIPOPHENOL COMPOUNDS AND USES THEREOF | INST NAT SANTE RECH MED (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3134421-B1 | NEW LIPOPHENOL COMPOUNDS AND USES THEREOF | INST NAT SANTE RECH MED (FR) | 2022-04-20 | — | — | EP | disclosed |
| US-11185514-B2 | Aqueous solution comprising a polyphenol | OPTERION HEALTH AG (CH) | 2021-11-30 | — | — | US | disclosed |
| US-7544497-B2 | Compositions for manipulating the lifespan and stress response of cells and organisms | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-06-09 | — | — | US | disclosed |
| US-20090099137-A1 | Anti-Inflammatory Compounds and Uses Thereof | MEDICON PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099137-A1 | Anti-Inflammatory Compounds and Uses Thereof | MEDICON PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2009012551-A1 | RESVERATROL COMPLEX AND PROCESS FOR THE PREPERATION | UNIÄO BRASILEIRA DE EDUCAÇAO E ASSITENCIA-MANTENEDORA DA PUCRS (BR) | 2009-01-29 | — | — | WO | disclosed |
| US-20090012130-A1 | Strategies for Designing Drugs that Target the Sir2 Family of Enzymes | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | BRIGHAM YOUNG UNIVERSITY | 2008-10-16 | — | — | US | disclosed |
| US-20060084135-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | BIOMOL INTERNATIONAL, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | BIOMOL INTERNATIONAL, INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099137-A1 | Anti-Inflammatory Compounds and Uses Thereof | TNF, NFKBIA, IL6 | LMNA 1744/4885MAPT 392/4885KDM4E 4668/4885 |
| US-11185514-B2 | Aqueous solution comprising a polyphenol | SORD, SI, AQP1 | LMNA 3193/4885MAPT 362/4885KDM4E 2998/4885 |
| US-12029706-B2 | Methods for treating mucopolysaccharidosis | GAA, MAN2B1, IDUA | LMNA 567/4885MAPT 4009/4885KDM4E 3519/4885 |
| US-20060014705-A1 | Compositions and methods for selectively activating human sirtuins | SIRT1, SIRT7, SIRT5 | LMNA 1010/4885MAPT 3039/4885KDM4E 640/4885 |
| US-11419841-B2 | Uses of lipophenolic compounds | MALT1, LIPG, CCR1 | LMNA 3017/4885MAPT 4652/4885KDM4E 3919/4885 |
| US-20080255382-A1 | N-heterocyclic carbon-type ligand coupling in the presence of a base with benzyol halide and styrene coupling partners; resveratrol; increased stability for use in the food, cosmetic and pharmaceutical industries | RB1, SBK1, NADK | LMNA 1421/4885MAPT 4496/4885KDM4E 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.